
Plexium, a San Diego-based med-tech firm, pioneers first-in-class therapeutics via E3 ligases modulation.
Plexium, founded in San Diego, California, is a leading medical technology company focused on developing first-in-class therapeutics by modulating E3 ligases. The company's core mission is to push the boundaries of targeted protein degradation (TPD) to improve lives. Plexium offers a comprehensive TPD platform powered by proprietary high-throughput cell-based screening (uHTS) technology, enabling the rational design and discovery of monovalent protein degraders across various modalities. Their market focus includes addressing unmet medical needs through innovative pharmaceutical solutions.
Notable affiliated individuals include experienced scientists and industry leaders who drive Plexium's pioneering research and development efforts. The company has attracted significant investment from prominent venture capital firms, underscoring confidence in its groundbreaking approach. Key achievements include the successful development of their TPD platform and the advancement of multiple therapeutic candidates. Overall, Plexium's impact lies in its potential to revolutionize the treatment landscape for various diseases through targeted protein degradation.

Nurix
nurixtx.com

Neomorph
neomorph.com

Differentiated Therapeutics
dxtherapeutics.com

Biotheryx
biotheryx.com

Pliant Therapeutics
pliantrx.com

EpiBiologics
epibiologics.com

Arvinas
arvinas.com

Plexision
plexision.com

Vicinitas Therapeutics
vicinitastx.com

76Bio
76bio.com

ProFound Therapeutics
profoundtx.com

Epirium Bio
epirium.com

PAQ Therapeutics
paqtx.com

Plectix BioSystems

Lycia Therapeutics
lyciatx.com
Companies similar to Plexium include Nurix, Neomorph, Differentiated Therapeutics and Biotheryx.
Plexium was founded in 2018.
Plexium's headquarters is located in San Diego, CA, US.
Plexium's most recent funding round was for $102M (USD) in February 2022.
As of Feb 23, 2022, Plexium has raised a total of $165M (USD).
Plexium has 94 employees as of Feb 4, 2024.